Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Envoy Medical, Inc. (NASDAQ: COCH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a hearing health business focused on fully implanted hearing devices. Envoy Medical files reports and registration statements that describe its Esteem® fully implanted active middle ear implant (FI-AMEI), the investigational fully implanted Acclaim® cochlear implant, its financial condition, capital structure, and key risks.
Through its Forms 10-Q and 10-K, Envoy Medical presents detailed financial statements and management discussion of operations, including net revenues from the Esteem FI-AMEI and related components, research and development expenses tied to the Acclaim pivotal clinical trial, and general and administrative costs associated with operating as a public company. These periodic reports also discuss liquidity, capital resources, and risk factors relevant to investors evaluating COCH.
Current reports on Form 8-K capture material events such as FDA approval to expand the pivotal clinical trial for the fully implanted Acclaim cochlear implant to its final stage, notices and determinations related to Nasdaq listing requirements, equity and warrant financing transactions, and quarterly earnings announcements. Proxy materials on Schedule 14A outline shareholder proposals, including approvals related to warrant issuances under Nasdaq rules, and provide additional context on the company’s capital raising activities.
Envoy Medical has also filed registration statements on Form S-1 and Form S-3 covering offerings of Class A common stock, pre-funded warrants, and the resale of shares underlying private placement warrants. These documents describe the company as an emerging growth company and a smaller reporting company, and they summarize its business focus on fully implanted hearing technologies, including the Esteem FI-AMEI and the investigational Acclaim cochlear implant.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, such as key changes in revenues and expenses, updates on the Acclaim clinical trial, new financing arrangements, and material listing or regulatory developments. Users can quickly review Forms 10-K and 10-Q for an overview of Envoy Medical’s financial performance, scan 8-K filings for significant events, and examine registration statements and proxy materials for details on securities offerings and shareholder approvals, all with real-time updates from the SEC’s EDGAR system.
Envoy Medical (NASDAQ:COCH) announced the appointment of Robert Potashnick as Interim Chief Financial Officer, effective June 23, 2025. Potashnick, 45, will serve as the company's principal financial officer and principal accounting officer through his consulting entity Oasis Business Consulting LLC. He brings significant experience from previous CFO roles at Flutterbee Education Group and FOXO Technologies, along with positions at UnitedHealth Group and PricewaterhouseCoopers LLP. The appointment is structured through a Consulting Agreement on a fractional consultant basis.